KALIVIR‘s VET™ backbone uniquely enhances systemic delivery of the virus to cancer cells by using B cells as IV delivery vehicles.
One key component of the VET™ backbone is the expression of various chemokine receptors from vaccinia virus. Our chemokine receptor expressing vaccinia virus is able to infect B cells in circulation, and drive the infected B cells to traffic towards tumors that express matching chemokines instead of lymph nodes. Vaccinia virus in the infected B cells is protected from circulating antibodies, and therefore is able to reach the tumor safely via systemic delivery.